Michael Drazer

Awesome application of genomics + cancer bio

Good news for @alice.soragnilab.com, SFPM, and rare disease models. Bad news for mouse cancer enthusiasts (humans are unreliable models of mouse disease).

How would you prove causality, considering ~20% of patients over 70 have CHIP?

Christiana Fogg, 11.7 miles into the 2024 Stone Mill 50-miler. Photo: Dan Reichmann, MCRRC

In this edition of #ScienceAdviser, Science Immunology Senior Editor @cnfogg.bsky.social talks about how her love of running led her to be the subject of science—rather than the editor of it. Plus more of the best from @science.org and science: www.science.org/content/arti... 🧪

A study of gene expression in the living human brain - Molecular Psychiatry Molecular Psychiatry - A study of gene expression in the living human brain

Different results than those found in preserved samples www.nature.com/articles/s41...

Tracing the evolution of sequencing into the era of genomic medicine Nature Reviews Genetics, Published online: 15 August 2025; doi:10.1038/s41576-025-00884-5Extraordinary advances in genomic science have defined the twenty-first century, transforming our understanding of human biology in both health and disease. This timeline Perspective charts two decades of genomic innovation since the human genome reference sequence became available, highlighting the evolution of sequencing technologies and how they, combined with computational advances, paved the way for genomic medicine.

New online! Tracing the evolution of sequencing into the era of genomic medicine

In the ENHANCE-2 study, Magro/Aza did not improve OS of patients with TP53-mutated AML. buff.ly/8DeMMxH #hemesky

Comprehensive genome analysis and variant detection at scale using DRAGEN - Nature Biotechnology DRAGEN rapidly identifies diverse types of genetic variants.

DRAGEN rapidly identifies diverse types of genetic variants go.nature.com/4eXQRT1
rdcu.be/ezphs

Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer - PubMed Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer

In a recently published article in NEJM, Ari Rosenberg, MD, and Everett Vokes, MD, discuss the promise and complexities of the KEYNOTE-689 trial, which shows event-free survival benefits from pembrolizumab in curative-intent settings. @arirosenbergmd.bsky.social
pubmed.ncbi.nlm.nih.gov/40532147/

Transparent peer review to be extended to all of Nature’s research papers From today, all new submissions to Nature that are published will be accompanied by referees’ reports and author responses — to illuminate the process of producing rigorous science.

From today, all new submissions to Nature that are published will be accompanied by referees’ reports and author responses — to illuminate the process of producing rigorous science

https://go.nature.com/4kIRR01

+1

Guidelines for writing:

• Just get started—no writer's block; only getting started block
• Write for clarity first
• Write for elegance second
• Delete excess words
• Don't write and edit at same time
• OK for first drafts to stink
• Read your work aloud
• Get good sleep

In a study on world class performers, those who made it world class:

-Had more multisport than specialized practice
-Started their main sport later
-Accumulated less practice
-Initially progressed slower than national class peers

🚨 New research finds women with BRCA1/2 mutations who received textured breast implants after mastectomy face a 16x higher risk of developing BIA-ALCL, a rare lymphoma. Study highlights need for awareness years after surgery.

🔗 https://bit.ly/404WEk1

@bloodjournals.hematology.org

How awesome is this?!

JAMA Network Open @jamanetworkopen.com - an open access journal in the JAMA Network - is now on BlueSky!

#MedSky

CrossFilt: A Cross-species Filtering Tool that Eliminates Alignment Bias in Comparative Genomics Studies www.biorxiv.org/content/10.1... 🧬🖥️🧪 github.com/kennethabarr...

Elon/DJT break up is the biggest split since WHO/ICC

Classic.

@greenwell.bsky.social, your media training is working because I just saved your audiobook to my Spotify library. Keep fighting the good fight, this is an important issue.

Out today in @pnas.org! www.pnas.org/doi/10.1073/...

Science’s ‘Gollum effect’: PhDs bear brunt of territorial behaviour Nature - Survey respondents at all career stages report colleagues engaging in territorial and possessive behaviours — but early-career researchers are most often affected.

💍 The Gollum Effect: possessive behaviours, attempts to undermine others, and efforts to restrict access to data, resources or opportunities

https://go.nature.com/4mxAJvG

Key rules to achieve sustainable success:

1. Consistency trumps perfection.
2. Be a minimalist to be a maximalist.
3. Have a quiet ego.
4. Focus on the process, not results.
5. Establish a secure but flexible identity.
6. Stress + Rest = Growth

Hahahaha I knew you would appreciate that. Great meme as always

The 2016 paper is correct - the "what do with a D14 marrow" question is ripe for a randomized study, but - as was the case in 2016 - there is unfortunately little incentive to address this in the current US system.

Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course

Finally, there is the 2016 effort led by Dr. Estey that beautifully summarizes this question. It's cited in the NCCN AML guidelines, but isn't covered in the NCCN discussion section to the extent it should be.

pmc.ncbi.nlm.nih.gov/articles/PMC...

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia - PubMed A day 14 BM biopsy may have suboptimal sensitivity for the detection of residual leukemia. Some patients with an IR on day 14 may not require re-induction chemotherapy, but instead, may benefit from c...

In addition to this study from the Duke team, which similarly questioned the utility of re-inducing these patients (and the associated morbidity and mortality) versus awaiting count recovery.

pubmed.ncbi.nlm.nih.gov/23046833/

Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia - PubMed Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia

And this paper, which identified a subset of patients whose day 14 marrows were ominous (but improved by day 21 and who ultimately entered remission at count recovery):

pubmed.ncbi.nlm.nih.gov/18519513/

Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia The diagnosis of acute myeloid leukemia (AML) can be made based on peripheral blood or bone marrow blasts. In this review, we will discuss the role of bone marrow evaluation and peripheral blood monit...

Some really great stuff - even years later - including this fantastic 2018 paper reviewing the evidence for/against the day 14 marrow:

pmc.ncbi.nlm.nih.gov/articles/PMC...

Was discussing a recent case with a colleague when the utility of the day 14 marrow in our patients undergoing intensive induction for AML was discussed. Prompted a return to the "old" literature on this topic, much of which was written by Eli Estey (and @drchrishourigan.bsky.social).

Vicar of Christ